$IKT Long. Daily chart

IKT (Inhibikase Therapeutics) Long:

- On 06/16/2021 priced a public offering of 15 million common shares at $3 per share
- On 07/26/2021 received clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients.

- Unusual volume recently
- Bullish divergence with RSI